PHOTO
Kuwait: The British Embassy in Kuwait hosted an exchange of contracts ceremony between a British healthcare company GSK and a Kuwaiti global science-led pharmaceutical medical products distribution expert, Safwan Company. Her Majesty’s Ambassador to the State of Kuwait, Belinda Lewis, witnessed the exchanging of contracts between the two parties.
The new contract will authorise Safwan to efficiently, reliably, and safely import, store and distribute a wide range of innovative, high-quality GSK medicines and vaccines widely prescribed in Kuwait.
Safwan will also employ a team of highly motivated professionals dedicated to supporting medical education, upskilling healthcare professionals, and managing the logistics and supply of market-leading GSK products to raise the standards of health and medicine in Kuwait.
Safwan Chairman and CEO, Mr Faisal Ali Al Mutawa, said: “We are proud to enter into this agreement with GSK, a globally-leading biopharmaceutical company that has established a strong track record and heritage in Kuwait. Our partnership with GSK helps unlock new opportunities to achieve our mission to improve patient health in our country.”
The agreement includes a wide range of medicines and vaccines that help prevent, treat or cure infectious diseases, auto-immune, HIV and anxiety related conditions.
GSK Country Manager for the Pharma Division in Kuwait, Mr Belal Ghattas, said: “We are committed to ensuring continuity in the supply of medicines and vaccines in Kuwait. Operating in Kuwait for more than 50 years, GSK is very proud of its contributions to advance human health. We are confident that our agreement with a leading Kuwait-based medical company like Safwan will enable us to provide better access to high-quality care and treatment for patients.”
GSK Country Manager for Consumer Healthcare in Kuwait, Mr Ahmed Abdeldaim, added: “We are very excited about our new partnership with Safwan, and are confident that this partnership will allow us to serve the local community more efficiently. In light of the challenges faced by the pandemic, we are prioritizing the most essential brands for treatment, including Panadol, and will ensure their availability for each and every patient in Kuwait.”
The British Ambassador to Kuwait, HM Belinda Lewis, said: “The United Kingdom is a global leader in life sciences and innovative biopharmaceuticals. Our pharmaceutical industry is at the forefront of developing lifesaving medicines and making them affordable and accessible around the world. GSK is a perfect example of this excellence. I congratulate GSK on their partnership with Safwan. I am delighted that this collaboration will lead to greater availability of GSK’s world-class products in Kuwait.
Her Majesty’s Trade Commissioner for the Middle East, Afghanistan and Pakistan Mr Simon Penney, said: “I am delighted to congratulate GSK on their collaboration with Safwan Trading in Kuwait. The UK is home to over 5800 life sciences companies including GSK. UK researchers and institutions are at the forefront of scientific exploration, invention and innovation in healthcare – most recently in the fight against Covid-19. The Department for International Trade team remains committed to supporting UK-Kuwait partnerships, and this is an excellent example of collaborative success.”
-Ends-
About GSK
GSK is a science-led global healthcare company with a special purpose-- to help people do more, feel better, and live longer. Globally and regionally, we have a proven track-record for providing high quality medicines, vaccines and consumer healthcare products.
GSK has a 300-year global legacy and more than 60 years of local presence in the Gulf region. Our goal is to be one of the world’s most innovative and trusted healthcare companies delivering high level products that patients and consumers depend on.
About GSK in Kuwait
GSK has supplied high quality vaccines and medicines to Kuwait for over 50 years to prevent, treat or cure infectious, respiratory, immune-degenerative and other diseases. In May 2021, Kuwait approved an emergency use authorization for a new GSK treatment for COVID-19.
About Safwan
Safwan Trading & Contracting Co., a subsidiary of Ali Abdulwahab Al Mutawa Commercial Co. (AAW), is one of the top leading companies in Kuwait in the health care business, representing a considerable number of well-known multinational principals. Safwan has been in business since 1967 and is recognized as a major supplier of pharmaceuticals, medical equipment and supplies, and laboratory products; from the health care sector to the Ministry of Health & other ministries, as well as public and private institutions. In 2005, Safwan was placed as the first company in its category to be enlisted in the Kuwait Stock Exchange.
About Ali Abdulwahab Al Mutawa Commercial Co. (AAW):
Ali Abdulwahab Al Mutawa Commercial Co. (AAW) is one of the largest trading and commercial companies in Kuwait, operating in seven diverse business sectors and distributes in Kuwait’s surging wholesale, retail and consumer market over 100 different global brands, including world-class brands such as Procter and Gamble, Clorox, Roche, Takeda, Biotronik, Nuxe, Bioderma, Nolte Group, La Cornue, Bosch, Siemens, The North Face, Coleman, Nike Store, The Athlete’s Foot, Crocs, Puma, Reebok, among many others.
AAW’s continuously growing business lines include Consumer Goods, Furniture, Kitchens, Home Appliances, Outdoor Gear and Equipment, Sports and Fashion, Real Estate, and Pharmaceuticals where it is a leading wholesale and retail distributor of pharmaceutical and medical products. It also holds a renowned portfolio of principals like Pfizer and Novo Nordisk distributed through its subsidiary Safwan Trading and Contracting (Safwan).
For more information, please visit: www.aaw.com
For media inquiries, please contact:
Nour Samawi
Bensirri PR
nour@bensirri.com
+965 99981334
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
